COMPANY NEWS
1 min read
REPLAY | FebriDx US Launch Update
Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales
Read article
News
Featured news
COMPANY NEWS
COMPANY NEWS
2 min read
100+ Locations and Growing: A Milestone for FebriDx® Adoption
FebriDx® has surpassed 100 healthcare locations across 18 states in the United States
Read article
COMPANY NEWS
1 min read
Lumos Achieves 250 Patient Milestone in FebriDx® Paediatric Study
Lumos has achieved enrolment of 250 patients in its BARDA-funded FebriDx® paediatric clinical study, triggering a US$670,000 milestone payment...
Read articleAll news
COMPANY NEWS
1 min read
USA Today | Not 'if' but 'when': Antibiotic resistance poses existential threat for modern medicine
Lumos’ FebriDx test has been identified as a useful tool in the fight to ‘outsmart’ antimicrobial...
Read article
COMPANY NEWS
3 min read
Lumos Receives US FDA Clearance for FebriDx®
Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care...
Read article
COMPANY NEWS
2 min read
Lumos Diagnostics Appoints Doug Ward As CEO
Ward to lead U.S. FebriDx launch pending FDA 510(k) clearance...
Read article
COMPANY NEWS
2 min read
Economic Evaluation of Lumos Diagnostics’ FebriDx Point-of-Care Test Highlights $2.5 Billion in Potential U.S. Healthcare Cost Savings Annually
Lumos Diagnostics (ASX: LDX) has today announced that the Journal of Health Economics...
Read article